Influenza B vaccine lineage selection - An optimized trivalent vaccine
MetadataShow full item record
Mosterín, H. A., Fonville, J., Russell, C., James, S., & Smith, D. (2016). Influenza B vaccine lineage selection - An optimized trivalent vaccine. Vaccine, 34 1617-1622. https://doi.org/10.1016/j.vaccine.2016.01.042
Epidemics of seasonal influenza viruses cause considerable morbidity and mortality each year. Various types and subtypes of influenza circulate in humans and evolve continuously such that individuals at risk of serious complications need to be vaccinated annually to keep protection up to date with circulating viruses. The influenza vaccine in most parts of the world is a trivalent vaccine, including an antigenically representative virus of recently circulating influenza A/H3N2, A/H1N1, and influenza B viruses. However, since the 1970s influenza B has split into two antigenically distinct lineages, only one of which is represented in the annual trivalent vaccine at any time. We describe a lineage selection strategy that optimizes protection against influenza B using the standard trivalent vaccine as a potentially cost effective alternative to quadrivalent vaccines.
quadrivalent, trivalent vaccine, influenza B, hedging, vaccine strain selection, decision tree
Sera used in this research were kindly provided by the following collaborators: for Australia by Dr. Ian Barr, WHO Collaborating Center, Melbourne, Australia, pediatric sera for the United States by Dr. Jackie Katz, WHO Collaborating Center, Atlanta, US, for Japan by Dr. Takato Odagiri, WHO Collaborating Center, Tokyo, Japan, for China by Dr. Yuelong Shu, WHO Collaborating Center, Beijing, China, for the United Kingdom by Dr. John Wood, NIBSC, Hertfordshire, UK. Additional thanks to Drs Nancy Cox, Michael Shaw, and Alexander Klimov. This work was supported by European Union FP7 program EMPERIE (22349). JMF is supported by a Fellowship in Biomedical Informatics from the Medical Research Council (UK) and a Junior Research Fellowship from Homerton College, Cambridge. Funded by: ERCPMC grant number: FP7 22349.
EC FP7 CP (278976)
National Institutes of Health (NIH) (via Mount Sinai School of Medicine (MSSM)) (HHSN272201400008C)
Wellcome Trust (100891/Z/13/Z)
Embargo Lift Date
External DOI: https://doi.org/10.1016/j.vaccine.2016.01.042
This record's URL: https://www.repository.cam.ac.uk/handle/1810/253813
Recommended or similar items
The following licence files are associated with this item: